Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 6, 2000

View Archived Issues

Tibolone improves auditory function in postmenopausal women

FDA informs Urologix of new developments concerning the Targis System

Apo A-IV peptide suppresses appetite in obese rats, offered for licensing

AstraZeneca explores novel strategy for treating diabetes and certain other disorders

NPY receptor antagonists with dihydropyridine structure disclosed by Bristol-Myers Squibb

Atridox periodontal therapy approved in E.U.

New series of NOS inhibitors in early development at Pfizer

Imidazole cytokine inhibitors in the pipeline at SmithKline Beecham

Zambon and Sheffield begin clinical program for MSI-ipratropium

New thrombin inhibitors presented by Merck & Co. research group

Orally active, selective iNOS inhibitors discovered at Glaxo Wellcome

Protein-tyrosine-phosphatases explored at AHP as novel target for diabetes Rx

New developments announced for AltaRex's ovarian cancer therapy

Glaxo discovers PPARgamma agonist with excellent pharmacological and pharmacokinetic profile

Medarex antibody therapy reduces inflammation in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...